Compare GDDY & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | DVA |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.0B |
| IPO Year | 2014 | 2002 |
| Metric | GDDY | DVA |
|---|---|---|
| Price | $79.02 | $149.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | $142.00 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.7M | 724.0K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 6.22 | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $7.94 | $3.85 |
| Revenue Next Year | $6.10 | $3.07 |
| P/E Ratio | ★ $13.00 | $15.32 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $73.06 | $101.00 |
| 52 Week High | $193.55 | $159.42 |
| Indicator | GDDY | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 50.72 |
| Support Level | $73.06 | $146.05 |
| Resistance Level | $93.65 | $152.31 |
| Average True Range (ATR) | 3.02 | 3.54 |
| MACD | 0.27 | -0.85 |
| Stochastic Oscillator | 9.27 | 42.07 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.